Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Status:
Terminated
Trial end date:
2020-07-29
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and
tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839
with the PARP inhibitor talazoparib in participants with advanced/metastatic solid tumors.